Cryptotanshinone has diverse effects on cell cycle events in melanoma cell lines with different metastatic capacity

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 1, 2011, Pages 17-27

  Chen, Lei ^a   Zheng, Shi Zhong ^a   Sun, Zhi Guang ^a   Wang, Ai Yun ^a   Huang, Chen Hu ^a   Punchard, Neville A ^c   Huang, Shi Le ^d   Gao, Xiang ^b   Lu, Yin ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b NANJING UNIVERSITY   (China)

^c UNIVERSITY OF EAST LONDON   (United Kingdom)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B16; B16BL6; Cell cycle arrest; Cryptotanshinone; Melanoma

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; B RAF KINASE; BROXURIDINE; CELL CYCLE PROTEIN; CELL DIVISION CYCLE 25 HOMOLOG C; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CRYPTOTANSHINONE; CYCLIN A1; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; LACTATE DEHYDROGENASE; LIPOCORTIN 5; PROTEIN P21; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CELL STRAIN B16BL6; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG STRUCTURE; FEMALE; FLOW CYTOMETRY; MELANOMA B16; MELANOMA CELL; METASTASIS; MOUSE; MUTATIONAL ANALYSIS; NICK END LABELING; NONHUMAN; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BROMODEOXYURIDINE; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUGS, CHINESE HERBAL; FEMALE; GENES, RAS; LUNG NEOPLASMS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PHENANTHRENES; PROTO-ONCOGENE PROTEINS B-RAF; SALVIA MILTIORRHIZA;

EID: 79959623733     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1440-8     Document Type: Article

References (29)

1. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445:851-857
2. Marquette A, Bagot M, Bensussan A, Dumaz N (2007) Recent discoveries in the genetics of melanoma and their therapeutic implications. Arch Immunol Ther Exp (Warsz) 55:363-372
3. Lens M (2008) Current clinical overview of cutaneous melanoma. Br J Nurs 17:300-305
4. Kaufmann WK, Nevis KR, Qu P, Ibrahim JG, Zhou T, Zhou Y, Simpson DA, Helms-Deaton J, Cordeiro-Stone M, Moore DT, Thomas NE, Hao H, Liu Z, Shields JM, Scott GA, Sharpless NE (2008) Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression. J Invest Dermatol 128:175-187 (Pubitemid 350249366)
5. Fan TP, Yeh JC, Leung KW, Yue PY, Wong RN (2006) Angiogenesis: from plants to blood vessels. Trends Pharmacol Sci 27:297-309 (Pubitemid 43850005)
6. Zhang F, Zheng W, Pi R, Mei Z, Bao Y, Gao J, Tang W, Chen S, Liu P (2009) Cryptotanshinone protects primary rat cortical neurons from glutamate-induced neurotoxicity via the activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. Exp Brain Res 193:109-118
7. Zhou L, Zuo Z, Chow MS (2005) Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 45:1345-1359 (Pubitemid 41643896)
8. Wang BE (2000) Treatment of chronic liver diseases with traditional Chinese medicine. J Gastroenterol Hepatol 15 Suppl:E67-70
9. Yu XY, Lin SG, Chen X, Zhou ZW, Liang J, Duan W, Chowbay B, Wen JY, Chan E, Cao J, Li CG, Zhou SF (2007) Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier. Curr Drug Metab 8:365-378
10. Hur JM, Shim JS, Jung HJ, Kwon HJ (2005) Cryptotanshinone but not tanshinone IIA inhibits angiogenesisin vitro. Exp Mol Med 37:133-137 (Pubitemid 40676923)
11. Kang BY, Chung SW, Kim SH, Ryu SY, Kim TS (2000) Inhibition of interleukin-12 and interferon-gamma production in immune cells by tanshinones from Salvia miltiorrhiza. Immunopharmacology 49:355-361
12. Lee DS, Lee SH, Noh JG, Hong SD (1999) Antibacterial activities of cryptotanshinone and dihydrotanshinone I from a medicinal herb, Salvia miltiorrhiza Bunge. Biosci Biotechnol Biochem 63:2236-2239
13. Ren Y, Houghton PJ, Hider RC, Howes MJ (2004) Novel diterpenoid acetylcholinesterase inhibitors from Salvia miltiorhiza. Planta Med 70:201-204 (Pubitemid 38445184)
14. Ryu SY, Oak MH, Kim KM (1999) Inhibition of mast cell degranulation by tanshinones from the roots of Salvia miltiorrhiza. Planta Med 65:654-655 (Pubitemid 29503235)
15. Wang AM, Sha SH, Lesniak W, Schacht J (2003) Tanshinone (Salviae miltiorrhizae extract) preparations attenuate aminoglycoside- induced free radical formation in vitro and ototoxicity in vivo. Antimicrob Agents Chemother 47:1836-1841 (Pubitemid 36637803)
16. Nizamutdinova IT, Lee GW, Son KH, Jeon SJ, Kang SS, Kim YS, Lee JH, Seo HG, Chang KC, Kim HJ (2008) Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells. Int J Oncol 33:485-491
17. Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ, Han DC, Kwon BM (2009) Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res 69:193-202
18. Zhang W, Li D, Mehta JL (2004) Role of AIF in human coronary artery endothelial cell apoptosis. Am J Physiol Heart Circ Physiol 286:H354-H358 (Pubitemid 38049499)
19. Melnikova VO, Bolshakov SV, Walker C, Ananthaswamy HN (2004) Genomic alterations in spontaneous and carcinogeninduced murine melanoma cell lines. Oncogene 23:2347-2356 (Pubitemid 38496790)
20. Hartwell LH, Weinert TA (1989) Checkpoints: controls that ensure the order of cell cycle events. Science 246:629-634 (Pubitemid 19283354)
21. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, Donehower LA, Elledge SJ (2000) Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 14:1448-1459 (Pubitemid 30421838)
22. Abbas T, Dutta A (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9:400-414
23. Rhind N, Russell P (2000) Chk1 and Cds1: linchpins of the DNA damage and replication checkpoint pathways. J Cell Sci 113(Pt 22):3889-3896 (Pubitemid 32194514)
24. Bartek J, Lukas J (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3:421-429 (Pubitemid 38340288)
25. Manni I, Mazzaro G, Gurtner A, Mantovani R, Haugwitz U, Krause K, Engeland K, Sacchi A, Soddu S, Piaggio G (2001) NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G2 arrest. J Biol Chem 276:5570-5576
26. Rigel DS, Carucci JA (2000) Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA Cancer J Clin 50:215-236; quiz 237-240
27. Casagrande F, Darbon JM (2001) Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol 61:1205-1215 (Pubitemid 32375112)
28. Ling YH, Jiang JD, Holland JF, Perez-Soler R (2002) Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol 62:529-538 (Pubitemid 36329371)
29. Mosaddik MA (2003) In vitro cytotoxicity of tanshinones isolated from Salvia miltiorrhiza Bunge against P388 lymphocytic leukemia cells. Phytomedicine 10:682-685